Mark Nestor1,2,3,4,5,6,7,8,9,10, Joel L Cohen1,2,3,4,5,6,7,8,9,10, Marina Landau1,2,3,4,5,6,7,8,9,10, Said Hilton1,2,3,4,5,6,7,8,9,10, Andreas Nikolis1,2,3,4,5,6,7,8,9,10, Syed Haq1,2,3,4,5,6,7,8,9,10, Maurizio Viel1,2,3,4,5,6,7,8,9,10, Bill Andriopoulos1,2,3,4,5,6,7,8,9,10, Inna Prygova1,2,3,4,5,6,7,8,9,10, Keith Foster1,2,3,4,5,6,7,8,9,10, Alessio Redaelli1,2,3,4,5,6,7,8,9,10, Philippe Picaut1,2,3,4,5,6,7,8,9,10. 1. Dr. Nestor is with the Miller School of Medicine at the University of Miami in Miami, Florida, and the Center for Cosmetic Enhancement and Center for Clinical and Cosmetic Research in Aventura, Florida. 2. Dr. Cohen is with AboutSkin Dermatology and DermSurgery in Greenwood Village and Lone Tree, Colorado and the University of California, Irvine, in Irvine, California. 3. Dr. Landau is with Wolfson Medical Center in Holon, Israel. 4. Dr. Hilton is with Dr. Hilton and Partner in Düsseldorf, Germany. 5. Dr. Nikolis is with the University of Montreal in Montreal, Québec, Canada. 6. Dr. Haq is with Invictus Humanus in London, United Kingdom. 7. Dr. Viel is with London Center for Aesthetic Surgery in London, United Kingdom. 8. Dr. Andriopoulos is with Galderma Aesthetics in Uppsala, Sweden. 9. Drs. Prygova, Foster, and Picaut are with Ipsen Pharma in Boulogne-Billancourt, France. 10. Dr. Redaelli is with Visconti di Modrone Medical Center in Milan, Italy.
Abstract
OBJECTIVE: We sought to analyze the current literature regarding time to onset and duration of effect of abobotulinumtoxinA (aboBoNT-A, Dysport®/Azzalure®) for upper facial aesthetic indications. METHODS: We conducted a systematic review of literature databases (PubMed/MEDLINE, Embase, Cochrane Library, and Google Scholar) to identify English-language publications relevant to: population (patients with aesthetic indications [including glabellar lines and wrinkles]); interventions (aboBoNT-A); comparators (no restrictions); outcomes (efficacy, including onset of action and duration of effect); and settings (clinical). A manual search of review paper bibliographies was performed. Structured data extraction was used to enable interstudy analysis. RESULTS: Overall, 42 original research papers relevant to aboBoNT-A onset and/or duration were identified. All 24 studies assessing efficacy within one week post-injection demonstrated some response at the first time point assessed, and all 37 studies assessing duration showed some response after 12 weeks. Although methodologies for assessing onset and duration differed, when outcomes were refined by reported mean/median, at least 50 percent of patients responding to treatment, or significance versus placebo or baseline at a given time point, onset was most often reported within 2 to 3 days (7 studies), and as early as 24 hours (2 studies). Duration was most often reported as four months (18 studies), although four studies provided evidence that aboBoNT-A efficacy was maintained at five months and three studies at or after six months post-injection. CONCLUSION: This review indicates that aboBoNT-A has a median onset of efficacy of 2 to 3 days and a longer duration of action (3-6 months across studies) than the current labelled minimum treatment interval (12 weeks).
OBJECTIVE: We sought to analyze the current literature regarding time to onset and duration of effect of abobotulinumtoxinA (aboBoNT-A, Dysport®/Azzalure®) for upper facial aesthetic indications. METHODS: We conducted a systematic review of literature databases (PubMed/MEDLINE, Embase, Cochrane Library, and Google Scholar) to identify English-language publications relevant to: population (patients with aesthetic indications [including glabellar lines and wrinkles]); interventions (aboBoNT-A); comparators (no restrictions); outcomes (efficacy, including onset of action and duration of effect); and settings (clinical). A manual search of review paper bibliographies was performed. Structured data extraction was used to enable interstudy analysis. RESULTS: Overall, 42 original research papers relevant to aboBoNT-A onset and/or duration were identified. All 24 studies assessing efficacy within one week post-injection demonstrated some response at the first time point assessed, and all 37 studies assessing duration showed some response after 12 weeks. Although methodologies for assessing onset and duration differed, when outcomes were refined by reported mean/median, at least 50 percent of patients responding to treatment, or significance versus placebo or baseline at a given time point, onset was most often reported within 2 to 3 days (7 studies), and as early as 24 hours (2 studies). Duration was most often reported as four months (18 studies), although four studies provided evidence that aboBoNT-A efficacy was maintained at five months and three studies at or after six months post-injection. CONCLUSION: This review indicates that aboBoNT-A has a median onset of efficacy of 2 to 3 days and a longer duration of action (3-6 months across studies) than the current labelled minimum treatment interval (12 weeks).
Authors: Vince Bertucci; Nowell Solish; Joely Kaufman-Janette; Steve Yoelin; Ava Shamban; Joel Schlessinger; Daniel Snyder; Conor Gallagher; Yan Liu; Gill Shears; Roman G Rubio Journal: J Am Acad Dermatol Date: 2019-11-29 Impact factor: 11.527